Castle Biosciences (CSTL) Operating Leases (2021 - 2025)
Historic Operating Leases for Castle Biosciences (CSTL) over the last 5 years, with Q3 2025 value amounting to $25.3 million.
- Castle Biosciences' Operating Leases rose 7222.79% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year increase of 7222.79%. This contributed to the annual value of $14.3 million for FY2024, which is 121.36% up from last year.
- Per Castle Biosciences' latest filing, its Operating Leases stood at $25.3 million for Q3 2025, which was up 7222.79% from $25.4 million recorded in Q2 2025.
- Castle Biosciences' 5-year Operating Leases high stood at $25.4 million for Q2 2025, and its period low was $6.5 million during Q2 2022.
- In the last 5 years, Castle Biosciences' Operating Leases had a median value of $13.5 million in 2023 and averaged $13.5 million.
- Per our database at Business Quant, Castle Biosciences' Operating Leases skyrocketed by 9177.47% in 2023 and then skyrocketed by 121.36% in 2024.
- Castle Biosciences' Operating Leases (Quarter) stood at $6.9 million in 2021, then skyrocketed by 67.14% to $11.5 million in 2022, then increased by 22.89% to $14.2 million in 2023, then rose by 1.21% to $14.3 million in 2024, then surged by 76.38% to $25.3 million in 2025.
- Its Operating Leases stands at $25.3 million for Q3 2025, versus $25.4 million for Q2 2025 and $14.0 million for Q1 2025.